PROMOTORFebruary 2, 2026Ni Made Saithanya Gitanjali Dhevi, Rofi Bramantyo, Septy Rianty Salsabilla Dwi Putri et al.
Depression is a psychological disorder that affects aspects of affection, physiology, cognition, and individual behavior, and has an impact on significant changes in daily life. Data from the Ministry of Health of the Republic of Indonesia (2023) shows a national prevalence of depression of 1.4%, with the age group of 15-24 years recording the highest rate of 2%. One approach that is considered...
Major Depressive Disorder is a common and disabling psychiatric illness whose pharmacological treatment options have historically been characterized by relatively low response rates. "Treatment-resistant depression" has emerged to describe patients whose depressive symptoms fail to respond to multiple courses of oral antidepressant medications. In 2019, the FDA approved intranasal esketamine as...
Classic serotonergic psychedelics such as LSD and psilocybin show promising antidepressant effects in controlled trials, but real-world data from routine clinical care remain limited. This study retrospectively analysed routine data from adults with treatment-resistant depressive and/or anxiety disorders who received a first standardized Psychedelic-assisted Psychotherapy (PAP) cycle with 100...
Background: Mindfulness-based interventions (MBIs) have demonstrated consistent efficacy in reducing anxiety and depression. However, the underlying psychological mechanisms explaining these effects particularly emotional regulation and resilience remain underexplored in Indian clinical populations. Objective: This study investigates the mediating roles of emotional regulation and resilience in...
Background: Acute suicidality is an emergency psychiatric condition that requires urgent treatment. Traditional treatment approaches, such as antidepressant pharmacotherapy and psychotherapy, take weeks to achieve optimal effectiveness, hence exposing patients in imminent crisis to significant risk. Ketamine is a fast-acting N-methyl-D-aspartate (NMDA) receptor antagonist that has been...
Ketamine and esketamine have been approved as an adjunctive therapy for treatment-resistant major depressive disorder with acute suicidal ideation and behavior in adults. The current paper aimed to systematically review the available data on their efficacy in children and adolescents. The MEDLINE was searched with the keyword 'esketamine' on July 5th, 2024 (by following the PRISMA statement)....
Background: Anxiety and depression are leading causes of disability in India, with nearly 15% of adults experiencing some form of mental morbidity. Despite existing pharmacological and psychotherapeutic treatments, accessibility, affordability, and cultural barriers persist. Mindfulness-Based Interventions (MBIs), adapted from the Mindfulness-Based Stress Reduction (MBSR) model, offer a...
The global mental health crisis has escalated to unprecedented levels, with stress, anxiety, and depression posing major public health concerns. Conventional interventions have shown limited success in addressing these multifaceted issues, prompting researchers to explore alternative solutions. Yoga Nidra (YN), a meditative practice, has gained momentum over the past decade as a potential...
Major depressive disorder and co-morbid substance use disorder represent a challenging dual diagnosis, characterized by persistent anhedonia, high relapse rates, and poor response to conventional antidepressants. The dextromethorphan-bupropion combination with synergistic glutamatergic and dopaminergic mechanisms provides a new treatment option. We present three male patients with alcohol or...
Convergent evidence suggests that disrupted reward processing may be associated with observed alterations in frontostriatal activity in persons with major depressive disorder (MDD). Replicated evidence suggests that glutamatergic modulators may benefit persons experiencing disrupted reward function compared to healthy controls (HC). Herein, we systematically reviewed functional magnetic...
Major depressive disorder (MDD) remains a leading global cause of disability, with substantial clinical and societal burden. Despite the wide availability of antidepressants, many patients experience inadequate response, partial remission, or treatment-resistant depression. Emerging pharmacological options beyond traditional monoaminergic agents have shown promise in phase 3 clinical trials,...
The neurotic disorders (e.g., depression, dysthymia, generalized anxiety disorder, panic disorder, agoraphobia, social anxiety, post-traumatic stress disorder, and obsessive-compulsive disorder) are costly and difficult to treat. Diagnosis is based on symptoms not biological causes. Here, we summarize New Zealand-based work developing EEG biomarkers and novel treatments. Working at the...
The growing percentage of people suffering from drug-resistant depression increases interest in alternative therapies, particularly the usage of psychedelics such as psilocybin. The main source of psilocybin is the Psilocybe cubensis species. Due to the potential therapeutic benefits of psilocybin and the legal restrictions on its possession and use in the form of fungal fruiting bodies, this...
Bipolar disorder affects approximately 40 million individuals worldwide, with depression being the most prominent phase of the illness. Owing to limited treatment options, bipolar depression remains a major public health concern, often causing significant functional impairment and increased suicide risk. Current therapies frequently lack rapid effectiveness, highlighting the need for novel...
Second-generation mindfulness-based interventions (SG-MBIs), which integrate ethical and moral practices, have emerged as promising treatments for depressive and anxiety symptoms. This meta-analysis aims to evaluate the effectiveness of SG-MBIs in reducing depression and anxiety among adults. We conducted a meta-analysis of randomized controlled trials (RCTs) including adults from clinical...
Since 2000, rates of suicide and opioid overdose have sharply increased. Approximately one-third of individuals with major depressive disorder (MDD) experience treatment-resistant depression (TRD), highlighting the urgent need for novel therapeutic approaches. This review synthesizes pivotal preclinical and clinical findings on low-dose ketamine's rapid antidepressant effects and examines...
MDD can affect anyone regardless of age, and it often starts during late teens or early adulthood. Although some patients with MDD have an adequate response to medications, only approximately 50% respond to the first treatment, and approximately 30% do not achieve remission despite multiple interventions. Several strategies exist for treating patients who have failed multiple first-line agents,...
The development of novel, rapid-acting treatments and the resurgence of interest in the therapeutic potential of psychedelic-like compounds has stimulated excitement and enthusiasm within the pharmaceutical industry, and provided new hope for millions of individuals suffering with mental illness such as major depressive disorder and post-traumatic stress disorder. This review summarizes the...
Depression is highly prevalent among university students worldwide, yet evidence from Afghanistan is limited. This study examined the protective roles of spirituality, mindfulness, and hope against depression among 450 undergraduate and master’s students from four universities in Kabul during the 2025 academic year. The sample was predominantly young adults, with 43.1% aged 18–22 years and...
CureusJanuary 31, 2026Lukasz Siwek, Marta Nowocien, Barbara Balajewicz et al.
Psilocybin is a psychoactive chemical compound that exerts its effects through the activation of serotonergic receptors. It occurs naturally in mushrooms of the genus Psilocybe. Despite its potential medical applications, this substance is regarded as a drug with no recognized medical use. Depression constitutes a psychiatric disorder of substantial global burden, affecting millions of...